AH
Anlon Healthcare Ltd (AHCL)
₹25.89
Mkt cap
₹1,376 Cr
P/E ratio
38.60
P/B
5.35
Div yield
0.00%
ROE
18.40%
ROCE
20.80%
EPS (TTM)
₹0.67
Book value
₹5
52W range
10–37
Sector
Healthcare
Price history
Previous close
Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in the manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs). [1]
NSE AHCLBSE 544497
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−30.48% from high₹26
₹10+149.66% from low₹37
Current
₹25.89
Prev close
₹25.11
Day
+3.11%
Price performance
1D
+3.39%
1W
+1.56%
1M
−28.66%
3M
+78.79%
6M
+93.30%
1Y
+107.18%
YTD
+67.36%
Financials
Revenue, profit & margin
P/E ratio
38.6×
AHCL is 12% above the sector median of 34.4×
AHCL38.6×
Sector median34.4×
| Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|
| Sales | 49 | 33 | 52 | 36 | 51 | 88 | 106 | |
| Expenses | 32 | 27 | 38 | 23 | 36 | 72 | 80 | |
| Operating Profit | 17 | 6 | 14 | 12 | 15 | 16 | 25 | |
| OPM % | 35% | 19% | 26% | 35% | 30% | 18% | 24% | |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 1 | |
| Depreciation | 1 | 0 | 0 | 0 | 0 | 1 | 1 | |
| Profit before tax | 15 | 5 | 12 | 11 | 14 | 14 | 23 | |
| Tax % | -7% | 29% | 25% | 51% | 23% | 39% | 27% | |
| Net Profit | 17 | 4 | 9 | 5 | 11 | 8 | 17 | |
| EPS in Rs | 0.42 | 0.09 | 0.18 | 0.10 | 0.20 | 0.13 | 0.25 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202652.68%Promoter
Promoters52.68%
FIIs0.99%0.68
DIIs0.30%0.93
Public46.02%1.59
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Anlon Healthcare | ₹25.89 | 38.57 | 1,376 | 0.00% | 17 | +43.45% | 106 | +102.32% | 20.77% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports2
Concall transcripts11
Credit ratings1
Announcements5
Announcement under Regulation 30 (LODR)-Investor Presentation 30 Oct - We have attached herewith Investor Presentation as per Regulation 30 of SEBI (LODR) Regulation, 2015. Kindly take the same on your record. Thank you.Unaudited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended September 30, 2026 29 Oct - Board approved Q2 and H1 FY2026 standalone and consolidated results on October 29, 2026.Board Meeting Outcome for For Consider And Approve Unaudited Standalone And Consolidated Financial Statement For The Quarter Ended September 30, 2026 29 Oct - Board approved unaudited standalone and consolidated results for quarter and half year ended September 30, 2026.Announcement Regarding To Receive In- Principle Approval From Stock Exchange As Per Reg. 29 Of SEBI (LODR) Regulation, 2015 29 Oct - NSE and BSE gave in-principle approval for 8,05,35,651 equity shares under proposed share swap.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 26 Oct - Earnings call scheduled on 3 November 2026 at 5:00 PM to discuss Q2/H1 FY27 results.